Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Industry News

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

AI in the ICU: Algorithm Aims to Guide Glucose Control After Cardiac Surgery

Caitlin E. Cox

June 10, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Advertisement

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

TCTMD’s Top 10 Most Popular Stories for July 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

AI in the ICU: Algorithm Aims to Guide Glucose Control After Cardiac Surgery

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content